Genetic variations in the Vitamin D receptor predict type 2 diabetes and myocardial infarction in a community-based population: The tromsø study

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Zostautiene, Ieva ^a,b   Jorde, Rolf ^a,b   Schirmer, Henrik ^a,b   Mathiesen, Ellisiv Bøgeberg ^a,b   Njølstad, Inger ^a   Løchen, Maja Lisa ^a   Wilsgaard, Tom ^a   Joakimsen, Ragnar Martin ^a,b   Kamycheva, Elena ^a,b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; DNA; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR;

ADULT; ALLELE; ARTICLE; COMMUNITY; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; GENETIC DIFFERENCE; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HOMOZYGOTE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NORWEGIAN (PEOPLE); PREDICTION; PROPORTIONAL HAZARDS MODEL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; VITAMIN BLOOD LEVEL; AGED; CASE CONTROL STUDY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; GENETICS; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASMS; NORWAY; PARTICIPATORY RESEARCH; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

AGED; CASE-CONTROL STUDIES; COMMUNITY-BASED PARTICIPATORY RESEARCH; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEOPLASMS; NORWAY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, CALCITRIOL; SURVIVAL RATE;

EID: 84956881929     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0145359     Document Type: Article

References (48)

1. Pludowski P, Holick MF, Pilz S, Wagner CL, Hollis BW, Grant WB, et al. Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmunity reviews. 2013; 12(10):976-89. doi: 10.1016/j. autrev.2013.02.004 PMID: 23542507.
2. Anderson JL, May HT, Horne BD, Bair TL, Hall NL, Carlquist JF, et al. Relation of Vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. The American journal of cardiology. 2010; 106(7):963-8. doi: 10.1016/j.amjcard.2010.05.027 PMID: 20854958.
3. Hutchinson MS, Figenschau Y, Njolstad I, Schirmer H, Jorde R. Serum 25-hydroxyVitamin D levels are inversely associated with glycated haemoglobin (HbA(1c)). The Tromso Study. Scandinavian journal of clinical and laboratory investigation. 2011; 71(5):399-406. doi: 10.3109/00365513.2011.575235 PMID: 21517716.
4. Schottker B, Haug U, Schomburg L, Kohrle J, Perna L, Muller H, et al. Strong associations of 25-hydroxyVitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. The American journal of clinical nutrition. 2013; 97(4):782-93. doi: 10.3945/ajcn. 112.047712 PMID: 23446902.
5. Hutchinson MS, Grimnes G, Joakimsen RM, Figenschau Y, Jorde R. Low serum 25-hydroxyVitamin D levels are associated with increased all-cause mortality risk in a general population: The Tromso study. European journal of endocrinology/European Federation of Endocrine Societies. 2010; 162(5):935- 42. doi: 10.1530/EJE-09-1041 PMID: 20185562.
6. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. Bmj. 2014; 348:g2035. doi: 10.1136/bmj.g2035 PMID: 24690624.
7. Saccone D, Asani F, Bornman L. Regulation of the Vitamin D receptor gene by environment, genetics and epigenetics. Gene. 2015; 561(2):171-80. doi: 10.1016/j.gene.2015.02.024 PMID: 25682935.
8. Chuang JC, Cha JY, Garmey JC, Mirmira RG, Repa JJ. Research resource: nuclear hormone receptor expression in the endocrine pancreas. Molecular endocrinology. 2008; 22(10):2353-63. doi: 10.1210/me.2007-0568 PMID: 18669644.
9. Chen S, Glenn DJ, Ni W, Grigsby CL, Olsen K, Nishimoto M, et al. Expression of the Vitamin D receptor is increased in the hypertrophic heart. Hypertension. 2008; 52(6):1106-12. doi: 10.1161/HYPERTENSIONAHA.108.119602 PMID: 18936343.
10. Hossein-nezhad A, Spira A, Holick MF. Influence of Vitamin D status and Vitamin D3 supplementation on genome wide expression of white blood cells: A randomized double-blind clinical trial. PloS one. 2013; 8(3):e58725. doi: 10.1371/journal.pone.0058725 PMID: 23527013.
11. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, et al. Common genetic determinants of Vitamin D insufficiency: A genome-wide association study. Lancet. 2010; 376(9736):180-8. doi: 10.1016/S0140-6736(10)60588-0 PMID: 20541252.
12. Pilz S, Kienreich K, Rutters F, de Jongh R, van Ballegooijen AJ, Grubler M, et al. Role of Vitamin D in the development of insulin resistance and type 2 diabetes. Current diabetes reports. 2013; 13(2):261- 70. doi: 10.1007/s11892-012-0358-4 PMID: 23264189.
13. Van Belle TL, Gysemans C, Mathieu C. Vitamin D and diabetes: The odd couple. Trends in endocrinology and metabolism: TEM. 2013; 24(11):561-8. doi: 10.1016/j.tem.2013.07.002 PMID: 23972673.
14. Gangula PR, Dong YL, Al-Hendy A, Richard-Davis G, Montgomery-Rice V, Haddad G, et al. Protective cardiovascular and renal actions of Vitamin D and estrogen. Frontiers in bioscience. 2013; 5:134-48.
15. Gardner DG, Chen S, Glenn DJ. Vitamin D and the heart. American journal of physiology Regulatory, integrative and comparative physiology. 2013; 305(9):R969-R977. doi: 10.1152/ajpregu.00322.2013 PMID: 24026071.
16. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nature reviews Cancer. 2007; 7(9):684-700. PMID: 17721433.
17. Hansen CM, Binderup L, Hamberg KJ, Carlberg C. Vitamin D and cancer: effects of 1, 25(OH)2D3 and its analogs on growth control and tumorigenesis. Frontiers in bioscience: A journal and virtual library. 2001; 6:D820-48.
18. Li L, Wu B, Liu JY, Yang LB. Vitamin D receptor gene polymorphisms and type 2 diabetes: A meta-analysis. Archives of medical research. 2013; 44(3):235-41. doi: 10.1016/j.arcmed.2013.02.002 PMID: 23506721.
19. Ahn J, Albanes D, Berndt SI, Peters U, Chatterjee N, Freedman ND, et al. Vitamin D-related genes, serum Vitamin D concentrations and prostate cancer risk. Carcinogenesis. 2009; 30(5):769-76. doi: 10. 1093/carcin/bgp055 PMID: 19255064.
20. Kostner K, Denzer N, Muller CS, Klein R, Tilgen W, Reichrath J. The relevance of Vitamin D receptor (VDR) gene polymorphisms for cancer: A review of the literature. Anticancer research. 2009; 29 (9):3511-36. PMID: 19667145.
21. Buttigliero C, Monagheddu C, Petroni P, Saini A, Dogliotti L, Ciccone G, et al. Prognostic role of Vitamin D status and efficacy of Vitamin D supplementation in cancer patients: A systematic review. The oncologist. 2011; 16(9):1215-27. doi: 10.1634/theoncologist.2011-0098 PMID: 21835895.
22. Ortlepp JR, Krantz C, Kimmel M, von Korff A, Vesper K, Schmitz F, et al. Additive effects of the chemokine receptor 2, Vitamin D receptor, interleukin-6 polymorphisms and cardiovascular risk factors on the prevalence of myocardial infarction in patients below 65 years. International journal of cardiology. 2005; 105(1):90-5. PMID: 16207551.
23. Van Schooten FJ, Hirvonen A, Maas LM, De Mol BA, Kleinjans JC, Bell DA, et al. Putative susceptibility markers of coronary artery disease: Association between VDR genotype, smoking, and aromatic DNA adduct levels in human right atrial tissue. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 1998; 12(13):1409-17.
24. Ferrarezi DA, Bellili-Munoz N, Dubois-Laforgue D, Cheurfa N, Lamri A, Reis AF, et al. Allelic variations of the Vitamin D receptor (VDR) gene are associated with increased risk of coronary artery disease in type 2 diabetics: The DIABHYCAR prospective study. Diabetes & metabolism. 2013; 39(3):263-70.
25. Vaidya A, Sun B, Forman JP, Hopkins PN, Brown NJ, Kolatkar NS, et al. The Fok1 Vitamin D receptor gene polymorphism is associated with plasma renin activity in Caucasians. Clinical endocrinology. 2011; 74(6):783-90. doi: 10.1111/j.1365-2265.2011.03991.x PMID: 21521263.
26. Perna L, Hoffmeister M, Schottker B, Arndt V, Haug U, Holleczek B, et al. Vitamin D receptor polymorphism and colorectal cancer-specific and all-cause mortality. Cancer epidemiology. 2013; 37(6):905-7. doi: 10.1016/j.canep.2013.09.007 PMID: 24075799.
27. Levin GP, Robinson-Cohen C, de Boer IH, Houston DK, Lohman K, Liu Y, et al. Genetic variants and associations of 25-hydroxyVitamin D concentrations with major clinical outcomes. Jama. 2012; 308 (18):1898-905. doi: 10.1001/jama.2012.17304 PMID: 23150009.
28. Vimaleswaran KS, Power C, Hypponen E. Interaction between Vitamin D receptor gene polymorphisms and 25-hydroxyVitamin D concentrations on metabolic and cardiovascular disease outcomes. Diabetes & metabolism. 2014; 40(5):386-9.
29. Thelle DS, Foorde OH, Try K, Lehmann EH. The Tromsoo heart study. Methods and main results of the cross-sectional study. Acta medica Scandinavica. 1976; 200(1-2):107-18. PMID: 785953.
30. Jacobsen BK, Eggen AE, Mathiesen EB, Wilsgaard T, Njolstad I. Cohort profile: The Tromso Study. International journal of epidemiology. 2012; 41(4):961-7. doi: 10.1093/ije/dyr049 PMID: 21422063.
31. Berntsen GK, Fonnebo V, Tollan A, Sogaard AJ, Magnus JH. Forearm bone mineral density by age in 7, 620 men and women: The Tromso study, a population-based study. American journal of epidemiology. 2001; 153(5):465-73. PMID: 11226978.
32. Jorde R, Schirmer H, Wilsgaard T, Joakimsen RM, Mathiesen EB, Njolstad I, et al. Polymorphisms related to the serum 25-hydroxyVitamin D level and risk of myocardial infarction, diabetes, cancer and mortality. The Tromso Study. PloS one. 2012; 7(5):e37295. doi: 10.1371/journal.pone.0037295 PMID: 22649517.
33. Kulathinal S, Karvanen J, Saarela O, Kuulasmaa K. Case-cohort design in practice-experiences from the MORGAM Project. Epidemiologic perspectives & innovations: EP+I. 2007; 4:15.
34. Joseph J, Svartberg J, Njolstad I, Schirmer H. Incidence of and risk factors for type-2 diabetes in a general population: The Tromso Study. Scandinavian journal of public health. 2010; 38(7):768-75. doi: 10. 1177/1403494810380299 PMID: 20696770.
35. Mannsverk J, Wilsgaard T, Njolstad I, Hopstock LA, Lochen ML, Mathiesen EB, et al. Age and gender differences in incidence and case fatality trends for myocardial infarction: A 30-year follow-up. The Tromso Study. European journal of preventive cardiology. 2012; 19(5):927-34.
36. Evans A, Salomaa V, Kulathinal S, Asplund K, Cambien F, Ferrario M, et al. MORGAM (an international pooling of cardiovascular cohorts). International journal of epidemiology. 2005; 34(1):21-7. PMID: 15561751.
37. Borch KH, Braekkan SK, Mathiesen EB, Njolstad I, Wilsgaard T, Stormer J, et al. Abdominal obesity is essential for the risk of venous thromboembolism in the metabolic syndrome: The Tromso study. Journal of thrombosis and haemostasis: JTH. 2009; 7(5):739-45. doi: 10.1111/j.1538-7836.2008.03234.x PMID: 19036065.
38. Grimnes G, Almaas B, Eggen AE, Emaus N, Figenschau Y, Hopstock LA, et al. Effect of smoking on the serum levels of 25-hydroxyVitamin D depends on the assay employed. European journal of endocrinology/European Federation of Endocrine Societies. 2010; 163(2):339-48. doi: 10.1530/EJE-10-0150 PMID: 20479012.
39. Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. American journal of epidemiology. 2009; 169(4):505-14. doi: 10. 1093/aje/kwn359 PMID: 19126586.
40. Cheskis B, Freedman LP. Ligand modulates the conversion of DNA-bound Vitamin D3 receptor (VDR) homodimers into VDR-retinoid X receptor heterodimers. Molecular and cellular biology. 1994; 14 (5):3329-38. PMID: 8164684.
41. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PI. SNAP: A web-based tool for identification and annotation of proxy SNPs using HapMap. Bioinformatics. 2008; 24(24):2938- 9. doi: 10.1093/bioinformatics/btn564 PMID: 18974171.
42. Geer LY, Marchler-Bauer A, Geer RC, Han L, He J, He S, et al. The NCBI BioSystems database. Nucleic acids research. 2010; 38(Database issue):D492-6. doi: 10.1093/nar/gkp858 PMID: 19854944.
43. Pescador N, Perez-Barba M, Ibarra JM, Corbaton A, Martinez-Larrad MT, Serrano-Rios M. Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. PloS one. 2013; 8(10):e77251. doi: 10.1371/journal.pone.0077251 PMID: 24204780.
44. Gandini S, Gnagnarella P, Serrano D, Pasquali E, Raimondi S. Vitamin D receptor polymorphisms and cancer. Advances in experimental medicine and biology. 2014; 810:69-105. PMID: 25207361.
45. Xu Y, He B, Pan Y, Deng Q, Sun H, Li R, et al. Systematic review and meta-analysis on Vitamin D receptor polymorphisms and cancer risk. Tumour biology: The journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35(5):4153-69.
46. Slattery ML, Herrick J, Wolff RK, Caan BJ, Potter JD, Sweeney C. CDX2 VDR polymorphism and colorectal cancer. Cancer epidemiology, biomarkers & prevention: A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007; 16 (12):2752-5.
47. Barry EL, Rees JR, Peacock JL, Mott LA, Amos CI, Bostick RM, et al. Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of Vitamin D3 supplementation for increasing serum 25-hydroxyVitamin D levels in a randomized controlled trial. The Journal of clinical endocrinology and metabolism. 2014; 99(10):E2133-7. doi: 10.1210/jc.2014-1389 PMID: 25070320.
48. Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G. Tracking of serum 25-hydroxyVitamin D levels during 14 years in a population-based study and during 12 months in an intervention study. American journal of epidemiology. 2010; 171(8):903-8. doi: 10.1093/aje/kwq005 PMID: 20219763.